<DOC>
	<DOCNO>NCT02418793</DOCNO>
	<brief_summary>The purpose current Phase 1/2a single dose , dose-escalating study evaluate acute safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) property MOD-5014 adult subject moderate/severe congenital hemophilia A B . This single-dose , open label , dose-escalating study . Each dose cohort conclude safety review , follow escalation next dose cohort approve .</brief_summary>
	<brief_title>A Study Long-Acting r-Factor 7a ( Factor VIIa ) Adult Men With Hemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosis moderate severe congenital Hemophilia A B without inhibitor Diagnosis coagulation disorder Hemophilia A B Receipt immunomodulatory therapy within 3 month prior screen , exception Hepatitis C HIV therapy Have , within one month prior study drug administration , major surgical procedure ( e.g . orthopedic , abdominal ) elective surgery plan within study period Use anticoagulant arterial/venous obstruction and/or atrial fibrillation within 7 day prior first study drug administration Malignancy within past 5 year ( exclude nonmelanoma skin cancer )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Factor VII</keyword>
	<keyword>Factor VIIa</keyword>
	<keyword>Inhibitors</keyword>
	<keyword>Long Acting</keyword>
</DOC>